Ionis earnings on deck: Can Tryngolza justify blockbuster hype?

Ionis Pharmaceuticals is set to unveil its third-quarter earnings on November 4, with investors keen to determine whether the company's high-stakes bet on Tryngolza can turn around its recent stock slump. Analysts forecast a loss of $1.21 per share and revenue of $183.12 million, showing a significant decline from the previous quarter, when Ionis reported a $0.69 loss per share on $268 million in revenue.

The projected loss is 51% higher than the second quarter and 2% lower than the EPS estimates from last quarter, while revenue estimates remain stable. Tryngolza, FDA-approved in June 2026 to lower triglycerides and pancreatitis risk in severe hypertriglyceridemia patients, has shown early launch momentum despite the stock's 46% decline this year.

Analyst sentiment remains overwhelmingly bullish, with 21 out of 25 analysts rating shares as Buy and a mean price target of $84.13, indicating a 104% upside potential. The approval marks Ionis's first independent commercial rollout in a prevalent disease, signaling a shift from focusing on rare conditions. Investors will closely monitor prescription trends, payer coverage, and the company's confidence in achieving its $100 million to $110 million sales guidance for Tryngolza in 2026.

GSK's Hibsago hepatitis B treatment, partnered with Ionis, received FDA approval on October 20, providing a new royalty stream of 10% to 12% on sales. Roche's sefaxersen, showing positive Phase 3 data for IgA nephropathy, could also generate a high-teen to 20% royalty for Ionis. The upcoming earnings report will reveal if Ionis can maintain execution momentum and justify the premium valuation for Tryngolza's commercial success.